Aknowledgments This study was supported by grants from the Academy of Finland, Finska LŠkaresŠllskapet, evo-funds, Invalid Foundation, the Finnish Dental Society Apollonia, CIMO, Orion-Farmos Research Foundation, and Helsinki University. Michelle Spaan was during her fellowship supported by ErasmusMC-Scholarship from Erasmus University and by the Erasmus-Scholarship from the European Union. Maria Lores-Rodriquez and Alberto Viv— were supported by FaroGlobal.

References

1.Manthorpe R, Oxholm P, Prause JU, Schi¿dt. The Copenhagen criteria for SjšgrenÕs syndrome. Scand J Rheumatol Suppl. 1986;61:19Ð21.

2.Vitali CS, Bombardieri R, Jonsson R, et al. ClassiÞcation criteria for SjšgrenÕs syndrome: a revised version of the European criteria proposed by the AmericanÐEuropean Consensus Group. Ann Rheum Dis. 2002;61:554Ð8.

3.Locht H, Pelck R, Manthorpe R. Clinical manifesta-

tions correlated to the prevalence of autoantibodies in a large (n = 321) cohort of patients with primary SjšgrenÕs syndrome: a comparison of patients initially diagnosed according to the Copenhagen classiÞcation criteria with the AmericanÐEuropean consensus criteria. Autoimmun Rev. 2005;4: 276Ð81.

4.Oxholm P, Asmussen K. ClassiÞcation of disease manifestations in primary SjšgrenÕs syndrome: present status and a new proposal. Clin Rheumatol. 1995;14 Suppl 1:3Ð7.

5.Mariette X. Therapeutic potential for B-cell modulation in SjšgrenÕs syndrome. Rheum Dis Clin North Am. 2008;34:1025Ð33.

6.Fox PC, Speight PM. Current concepts of autoimmune exocrinopathy: immunologic mechanisms in the salivary pathology of SjogrenÕs syndrome. Crit Rev Oral Biol Med. 1996;7:144Ð58.

7.Fox PC. Autoimmune diseases and SjšgrenÕs syndrome: an autoimmune exocrinopathy. Ann NY Acad Sci. 2006;1098:15Ð21.

8.Amft N, Bowman SJ. Chemokines and cell trafÞcking in SjšgrenÕs syndrome. Scand J Immunol. 2001;54:62Ð9.

9.Horvath IF, Szodoray P, Zeher M. Primary SjšgrenÕs syndrome in men: clinical and immunological characteristic based on a large cohort of Hungarian patients. Clin Rheumatol. 2008;27:1479Ð83.

10.Konttinen YT, Spaan M, Stegaev V, Porola P, LorŽs M, Viv— A, Koskenpato K, Przybyla BD. Female dominance in SjšgrenÕs syndrome Ð a paradox and a new paradigm. In: Zeher M, Szodoray P, editors. SjšgrenÕs syndrome and associated disorders. Kerala, India: Transworld Research Network; 2009, pp. 59Ð77.

11. Fraser PA, Smaje LH. The organization of the salivary gland microcirculation. J Physiol. 1977;272;121Ð36.

12.Peen E, Haga HJ, Haugen AJ, Kahrs GE, Haugen M. The effect of a liquid diet on salivary ßow in primary SjšgrenÕs syndrome. Scand J Rheumatol. 2008;37:236Ð7.

13.Gallowitsch-Puerta M, Pavlov VA. Neuro-immune interactions via the cholinergic anti-inßammatory pathways. Life Sci. 2007;80:2325Ð9.

14.Tsukada T, Horovitch SJ, Montminy MR, Mandel G, Goodman RH. Structure of the human vasoactive intestinal polypeptide gene. DNA 1985 4: 293Ð300.

15.Konttinen YT, Sorsa T, Hukkanen M, et al. Topology of innervation of labial salivary glands by protein gene product 9.5- and synaptophysin-

immunoreactive nerves in patients with SjšgrenÕs syndrome. J Rheumatol. 1992;19:30Ð7.

16. Konttinen YT, Hukkanen M, Kemppinen P, et al. Peptide-containing nerves in labial salivary glands in SjšgrenÕs syndrome. Arthritis Rheum. 1992;35:815Ð30.

17.MŒnsson B, Nilsson BO, Ekstršm J. Effects of repeated infusions of substance P and vasoactive intestinal peptide on the weight of salivary glands subjected to atrophying inßuence in rats. Br J Pharmacol. 1990;101:853Ð8.

18.Tagawa T, Mohri M, Tagawa H, et al. Role of nitric oxide in substance P-induced vasodilation differs between the coronary and forearm circulation in humans. J Cardiovasc Pharmacol. 1997;29:546Ð5.

19.OÕShaughnessy MC, Vetsika EK, Inglis JJ, et al. The effect of substance P on nitric oxide release in a rheumatoid arthritis model. Inßamm Res. 2006;55:236Ð4.

20.Heaney LG, Cross LJ, Stanford CF, Ennis M. Substance P induces histamine release from human pulmonary mast cells. Clin Exp Allergy. 1995;25:179Ð8.

21.Payan DG. Receptor-mediated mitogenic effects

of substance P on cultured smooth muscle cells. Biochem Biophys Res Commun. 1985;130: 104Ð9.

22.Kumaran C, Shivakumar K. Calciumand superoxide anion-mediated mitogenic action of substance P on cardiac Þbroblasts. Am J Physiol Heart Circ Physiol. 2002;282:H1855Ð6.

23.Villablanca AC, Murphy CJ, Reid TW. Growthpromoting effects of substance P on endothelial

cells in vitro. Synergism with calcitonin generelated peptide, insulin, and plasma factors. Circ Res. 1994;75:1113Ð2.

ral pathway in pathogenesis of arthritis. Science 1987;20;235:893Ð5.

25.Ziche M, Morbidelli L, Pacini M, Geppetti P, Alessandri G, Maggi CA. Substance P stimulates

neovascularization in vivo and proliferation of cultured endothelial cells. Microvasc Res. 1990;40:264Ð78.

26.Lotz M, Vaughan JH, Carson DA. Effect of neuropeptides on production of inßammatory cytokines by human monocytes. Science 1988;241:1218Ð21.

27.Laurenzi MA, Persson MA, Dalsgaard CJ, Haegerstrand A. The neuropeptide substance P stimulates production of interleukin 1 in human blood monocytes: activated cells are preferentially inßuenced by the neuropeptide. Scand J Immunol.

and thromboxane release. Eur J Pharmacol. 1983;89:301Ð5.

30.Murris-Espin M, Pinelli E, Pipy B, Leophonte P, Didier A. Substance P and alveolar macrophages: effects on oxidative metabolism and eicosanoid production. Allergy 1995;50:334Ð9.

31.Ruff MR, Wahl SM, Pert CB. Substance P receptor-mediated chemotaxis of human monocytes. Peptides 1985;6 Suppl 2:107Ð11.

32.Bar-Shavit Z, Goldman R, Stabinsky Y, et al. Enhancement of phagocytosisÑa newly found activity of substance P residing in its N-terminal tetrapeptide sequence. Biochem Biophys Res Commun. 1980;94:1445Ð51.

33.Stanisz AM, Befus D, Bienenstock J. Differential effects of vasoactive intestinal peptide, substance P, and somatostatin on immunoglobulin synthesis and proliferations by lymphocytes from PeyerÕs patches, mesenteric lymph nodes, and spleen. J Immunol. 1986;136:152Ð6.

34.Zimmerman BJ, Anderson DC, Granger DN.

Neuropeptides promote neutrophil adherence to endothelial cell monolayers. Am J Physiol. 1992;263:G678Ð82.

35.Qian Y, Zeng BF, Zhang XL, Jiang Y. Substance P augments PGE2 and IL-6 production in titanium particles-stimulated Þbroblasts from hip periprosthetic membrane. J Biomed Mater Res A. 2007;83:401Ð6.

36.Cury PR, Canavez F, de Araœjo VC, Furuse C, de Araœjo NS. Substance P regulates the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in cultured human gingival Þbroblasts. J Periodontal Res. 2008;43:255Ð60.

37.Hecker-Kia A, Kolkenbrock H, Orgel D, Zimmermann B, Sparmann M, Ulbrich N.

P up-regulates matrix metalloproteinase-1 and down-regulates collagen in human lung Þbroblast. Exp Lung Res. 2007;33:151Ð67.

39.McCormack DG, Mak JC, Coupe MO, Barnes PJ. Calcitonin gene-related peptide vasodilation of human pulmonary vessels. J Appl Physiol. 1989;67:1265Ð70.

40.Zhang WZ, Yu SF, Zheng LF. Effects of calcitonin gene-related peptide on bone resorption mediated by interleukin-1. Chin Med J (Engl). 1994;107: 351Ð4.

41.Zaidi M, Fuller K, Bevis PJ, GainesDas RE, Chambers TJ, MacIntyre I. Calcitonin gene-related peptide inhibits osteoclastic bone resorption: a com-

parative study. Calcif Tissue Int. 1987;40:149Ð54. 42. Leighton B, Foot EA. The role of the sen-

sory peptide calcitonin-gene-related peptide(s) in skeletal muscle carbohydrate metabolism: effects of capsaicin and resiniferatoxin. Biochem J. 1995;307:707Ð12.

43.Haegerstrand A, Dalsgaard CJ, Jonzon B, Larsson O, Nilsson J. Calcitonin gene-related peptide stimulates proliferation of human endothelial cells. Proc Natl Acad Sci USA. 1990;87:3299Ð303.

44.Sarasa M, Terrado J, Mengod G, Climent S, Muniesa P, Palacios JM. Differential expression of alpha-CGRP and beta-CGRP genes within hypoglossal motoneurons in response to axotomy. Brain Res Mol Brain Res. 1996;35:269Ð77.

45.Hashimoto K, Uchida S, Yoshida H. Effects of calcitonin gene-related peptide on the adenylate cyclase system in cultured rat skeletal muscle cells. Life Sci. 1989;45:2183Ð92.

46.Buckley TL, Brain SD, Rampart M, Williams TJ. Time-dependent synergistic interactions between the vasodilator neuropeptide, calcitonin generelated peptide (CGRP) and mediators of inßammation. Br J Pharmacol. 1991;103:1515Ð9.

47.Hernanz A, Medina S, de Miguel E, Mart’n-Mola E. Effect of calcitonin gene-related peptide, neuropeptide Y, substance P, and vasoactive intestinal peptide on interleukin-1beta, interleukin-6 and tumor necrosis factor-alpha production by peripheral whole blood cells from rheumatoid arthritis and osteoarthritis patients. Regul Pept. 2003;115:19Ð24.

48.Brokaw JJ, White GW. Calcitonin gene-related peptide potentiates substance P-induced plasma extravasation in the rat trachea. Lung 1992;170: 85Ð93.

49.Foster CA, Mandak B, Kromer E, Rot A. Calcitonin

gene-related peptide is chemotactic for human T lymphocytes. Ann NY Acad Sci. 1992;657: 397Ð404.

50.Umeda Y, Arisawa M. Inhibition of natural killer activity by calcitonin gene-related peptide. Immunopharmacol Immunotoxicol. 1989;11: 309Ð20.

51.Komaru T, Ashikawa K, Kanatsuka H, Sekiguchi N, Suzuki T, Takishima T. Neuropeptide Y

modulates vasoconstriction in coronary microvessels in the beating canine heart. Circ Res. 1990;67: 1142Ð51.

52.Awad SJ, Einstein R, Potter EK, Richardson DP. The effects of neuropeptide Y on myocardial contractility and coronary blood ßow. Br J Pharmacol. 1991;104:195Ð201.

53.Walker MW, Ewald DA, Perney TM, Miller RJ.

Neuropeptide Y modulates neurotransmitter release and Ca2+ currents in rat sensory neurons. J Neurosci. 1988;8:2438Ð4.

54.Dewar HA, Zar MA, Oxley A. Neuropeptide Y and platelet aggregation by adrenaline. Life Sci. 1989;45:367Ð70.

55.Ubink R, Calza L, Hškfelt T. ÔNeuroÕ-peptides in glia: focus on NPY and galanin. Trends Neurosci. 2003;26:604Ð9.

56.Hansel DE, Eipper BA, Ronnett GV. Neuropeptide Y functions as a neuroproliferative factor. Nature 2001;410:940Ð4.

57.Sung CP, Arleth AJ, Feuerstein GZ. Neuropeptide Y upregulates the adhesiveness of human endothelial cells for leukocytes. Circ Res. 1991;68: 314Ð8.

58.Ganz MB, Perfetto MC, Boron WF. Effects of

mitogens and other agents on rat mesangial cell proliferation, pH, and Ca2+. Am J Physiol. 1990;259: F269Ð78.

59.Bedoui S, Kawamura N, Straub RH, et al. Relevance of neuropeptide Y for the immune crosstalk. J Neuroimmunol. 2003;134:1Ð11.

60.Fahrenkrug J. Gut/brain peptides in the genital tract: VIP and PACAP. Scand J Clin Lab Invest Suppl. 2001;234:35Ð9.

61.Rekik M, Delvaux M, Tack I, Frexinos J, Bueno L. VIP-induced relaxation of guinea-pig intestinal smooth muscle cells: sequential involvement of cyclic AMP and nitric oxide. Br J Pharmacol. 1996;118:477Ð84.

62.Gu ZF, Jensen RT, Maton PN. A primary role for protein kinase A in smooth muscle relaxation induced by adrenergic agonists and neuropeptides. Am J Physiol. 1992;263:G360Ð4.

63.Sawmiller DR, Henning RJ, Cuevas J, Dehaven WI, Vesely DL. Coronary vascular effects of vasoactive intestinal peptide in the isolated perfused rat heart. Neuropeptides 2004;38:289Ð97.

64.el Halawani ME, Pitts GR, Sun S, Silsby JL, Sivanandan V. Active immunization against vasoactive intestinal peptide prevents photo-induced prolactin secretion in turkeys. Gen Comp Endocrinol. 1996;104:76Ð83.

65.Ito H, Matsuda K, Sato A, Tohgi H. Cholinergic and VIPergic vasodilator actions of parasympathetic nerves on the thyroid blood ßow in rats. Jpn J Physiol. 1987;37:1005Ð17.

66.Fahrenkrug J, Schaffalitzky de Muckadell OB, Holst JJ, Jensen SL. Vasoactive intestinal polypeptide in vagally mediated pancreatic secretion

of ßuid and HCO3. Am J Physiol. 1979;237: E535Ð40.

67.Konturek SJ, Domschke S, Domschke W, WŸnsch E, Demling L. Comparison of pancreatic responses to portal and systemic secretin and VIP in cats. Am J Physiol. 1977;232:E156Ð8.

68.Felley CP, Qian JM, Mantey S, Pradhan T, Jensen RT. Chief cells possess a receptor with high afÞnity for PACAP and VIP that stimulates pepsinogen release. Am J Physiol. 1992;263:G901Ð7.

69.Bechtold DA, Brown TM, Luckman SM,

Piggins HD. Metabolic rhythm abnormalities in mice lacking VIP-VPAC2 signaling. Am J Physiol Regul Integr Comp Physiol. 2008;294: R344Ð51.

70.Gonzalez-Rey E, Delgado M. Role of vasoactive intestinal peptide in inßammation and autoimmunity. Curr Opin Investig Drugs. 2005;6:1116Ð23.

71.Felten SY, Felten DL, Bellinger DL, et al. Noradrenergic sympathetic innervation of lymphoid organs. Prog Allergy. 1998;43:14Ð36.

72.Livnat S, Felten SY, Carlson SL, Bellinger DL, Felten DL. Involvement of peripheral and central catecholamine systems in neuroimmune interactions. J Neuroimmunol. 1985;10:5Ð30.

73.Harrison S, Geppetti P. Substance P. Int J Biochem Cell Biol. 2001;33:555Ð76.

74.Sabbadini E, Berczi I. The submandibular gland: a key organ in the neuro-immuno-regulatory network?. Neuroimmunomodulation 1995;2:184Ð202.

75.Hokfelt T, Kuteeva E. Substance P: a neuropeptide. Am J Psychiatry. 2006;163:578.

76.Nelson DA, Bost KL. Non-neuronal mammalian tachykinin expression. Front Biosci. 2004;9: 2166Ð76.

77.Gerard NP, Garraway LA, Eddy RL, et al. Human substance P receptor (NK-1): organization of the gene, chromosome localization, and functional expression of cDNA clones. Biochemistry 1991;30:10640Ð6.

78.Hokfelt T, Kuteeva E. Substance P: a neuropeptide. Am J Psychiatry. 2006;163:578.

79.Van der Kleij HP, Ma D, Redegeld FA, Kraneveld AD, Nijkamp FP, Bienenstock J. Functional expression of neurokinin 1 receptors on mast cells induced by IL-4 and stem cell factor. J Immunol. 2003;171:2074Ð9.

80.Maggi CA. The mammalian tachykinin receptors. Gen Pharmacol. 1995;26:911Ð44.

81.Mcbillis P, Mitsuhashi M, Payan DG. Immunomodulation by tachykinin neuropeptides. Ann NY Acad Sci. 1990;594:85Ð94.

82.Daniel A, Nelson, Kenneth L Bost. Non-neuronal mammalian tachykinin expression. Front Biosci. 2004;9:2166Ð76.

83.Hershey AD, Dykema PE, Krause JE. Organization,

structure, and expression of the gene encoding the rat substance P receptor. J Biol Chem. 1991;266:4366Ð74.

84.Abe-Dohmae S, Takagi Y, Harada N. Autonomous expression of aromatase during development of mouse brain is modulated by neurotransmitters. J Steroid Biochem Mol Biol. 1997;61:299Ð306.

85.Peroutka SJ. Neurogenic inßammation and migraine: implications for the therapeutics. Mol Interv. 2005;5:304Ð11.

86.Ericsson A, Schalling M, McIntyre KR, et al.

Detection of neuropeptide Y and its mRNA in megakaryocytes: enhanced levels in certain autoimmune mice. Proc Natl Acad Sci USA. 1987;84:5585Ð9.

87.Ericsson A, Hemsen A, Lundberg JM, Persson H. Detection of neuropeptide Y-like immunoreactivity and messenger RNA in rat platelets: the effects of vinblastine, reserpine, and dexamethasone on NPY expression in blood cells. Exp Cell Res. 1991;192:604Ð11.

88.Lundberg JM, Tatemoto K. Pancreatic polypeptide family (APP, BPP, NPY and PYY) in relation to sympathetic vasoconstriction resistant to alpha-adrenoceptor blockade. Acta Physiol Scand. 1982;116:393Ð402.

89.Ekblad E, Edvinsson L, Wahlestedt C, Uddman R, HŒkanson R, Sundler F. Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve Þbers. Regul Pept. 1984;8:225Ð35.

90.Wheway J, Mackay CR, Newton RA, et al. A fundamental bimodal role for neuropeptide Y1 receptor in the immune system. J Exp Med. 2005;202:1527Ð38.

91.Barbany G, Friedman WJ, Persson H. Lymphocytemediated regulation of neurotransmitter gene expression in rat sympathetic ganglia. J Neuroimmunol. 1991;32:97Ð104.

92.Duan-Porter WD, Casciola-Rosen L, Rosen A. Autoantigens: the critical partner in initiating and propagating systemic autoimmunity. Ann NY Acad Sci. 2005;1062:127Ð36.

93.Lanzavecchia A. How can cryptic epitopes trigger autoimmunity? J Exp Med. 1995;181:1945Ð8.

94.Humphreys-Beher MG, Peck AB, Dang H, Talal N. The role of apoptosis in the initiation of the autoimmune response in SjšgrenÕs syndrome. Clin Exp Immunol. 1999;16:383Ð7.

95.Mircheff AK, Gierow JP, Lee LM, Lambert RW, Akashi RH, Hofman FM. Class II antigen expression by lacrimal epithelial cells. An updated working hypothesis for antigen presentation by epithelial cells. Invest Ophthalmol Vis Sci. 1991;32:2302Ð10.

96.Nakamura S, Hiroki A, Shinohara M. Aberrant expression of HLA-DR antigens on acinar and ductal epithelial cells of salivary glands in SjšgrenÕs syndrome. Nippon Rinsho. 1995;53:2407Ð11.

97.Yewdell JW, Anton LC, Bennink JR. Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? J Immunol. 1996;157:1823Ð6.

98.Yewdell JW. Serendipity strikes twice: the discovery and rediscovery of defective ribosomal products (DRiPS). Cell Mol Biol. 2005;51:635Ð41.

99.Schubert U, Ant—n LC, Gibbs J, Norbury CC, Yewdell JW, Bennink JR. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 2000;404:770Ð4.

100.von Muhlen CA, Tan EM. Tan. Autoantibodies in the diagnosis of systemic rheumatic diseases. Sem Arthritis Rheum. 1995;24:323Ð58.

101.Watanabe T, Tsuchida T, Kanda N, Mori K, Hayashi Y, Tamaki K. Anti-alpha-fodrin antibodies in Sjšgren syndrome and lupus erythematosus. Arch Dermatol. 1999;135:535Ð9.

102.Bacman S, Berra A, Sterin-Borda L, Borda E. Muscarinic acetylcholine receptor antibodies as a new marker of dry eye Sjšgren syndrome. Invest Ophthalmol Vis Sci. 2001;42:321Ð7.

103.El-Gehani F, Tena-Sempere M, Huhtaniemi I. Vasoactive intestinal peptide stimulates testosterone production by cultured fetal rat testicular cells. Mol Cell Endocrinol. 1998;140:175Ð8.

104.Xie Y, Wolff DW, Lin MF, Tu Y. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells. Mol Pharmacol. 2007;72: 73Ð85.

105.Degerman A, Chun D, Nguyen TB, et al. Local action of estrogen and thyroid hormone on vasoactive intestinal peptide (VIP) and galanin gene expression in the rat anterior pituitary. Neuropeptides 2002;36:50Ð7.

106.Tšrnwall J, Konttinen YT, Tuominen RK, Tšrnwall M. Protein kinase C expression in salivary gland acinar epithelial cells in SjšgrenÕs syndrome. Lancet 1997;349:1814Ð5.

107.Onoue S, Misaka S, Yamada S. StructureÐactivity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications. Naunyn-SchmiedebergÕs Arch Pharmacol. 2008;377:579Ð90.

108.Aunis D, Langley K. Physiological aspects of exocytosis in chromafÞn cells of the adrenal medulla. Acta Physiol Scand. 1999;167:89Ð97.

109.Hornsby PJ. Aging of the human adrenal cortex. Sci Aging Knowledge Environ. 2004;35:re6.

110.Virtanen I, Korhonen M, PetŠjŠniemi N, et al. Laminin isoforms in fetal and adult human adrenal cortex. J Clin Endocrinol Metab. 2003;88:4960Ð6.

111.Kroboth PD, Salek FS, Pittenger AL, Fabian TJ, Frye RF. DHEA and DHEA-S: a review. J Clin Pharmacol. 1999;39:327Ð48.

112.Miller WL. Androgen biosynthesis from cholesterol to DHEA. Mol Cell Endocrinol. 2002;198:7Ð14.

113.Bornstein SR, Haidan A, Ehrhart-Bornstein M. Cellular communication in the neuro-adrenocortical axis: role of vasoactive intestinal polypeptide (VIP). Endocr Res. 1996;22:819Ð29.

114.Connell JM, Davies E. The new biology of aldosterone. J Endocrinol. 2005;186:1Ð20.

115.Schinner S, Willenberg HS, Krause D, et al. Adipocyte-derived products induce the transcription

of the StAR promoter and stimulate aldosterone and cortisol secretion from adrenocortical cells through the Wnt-signaling pathway. Int J Obes (Lond). 2007;31:864Ð70.

116.Gell JS, Oh J, Rainey WE, Carr BR. Effect of estradiol on DHEAS production in the human adrenocortical cell line, H295R. J Soc Gynecol Investig. 1998;5:144Ð8.

117.Kristiansen SB, Endoh A, Casson PR, Buster JE, Hornsby PJ. Induction of steroidogenic enzyme genes by insulin and IGF-I in cultured adult human adrenocortical cells. Steroids. 1997;62:258Ð65.

118.Brown TJ, Ginz B, Oakey RE. Effects of polypeptide hormone preparations on steroid production by the human foetal adrenal gland during superfusion. J Endocrinol. 1978;79:60Ð1.

119.Herrmann M, Scholmerich J, Straub RH. Inßuence of cytokines and growth factors on distinct steroidogenic enzymes in vitro: a short tabular

data collection. Ann NY Acad Sci. 2002;966: 166Ð86.

of adrenocortical steroidogenesis. Endocr Rev. 1998;19:101Ð43.

121.Gonz‡lez-Hern‡ndez JA, Bornstein SR, EhrhartBornstein M, Geschwend JE, Adler G, Scherbaum WA. Macrophages within the human adrenal gland. Cell Tissue Res. 1994;278:201Ð5.

122.Hayashi Y, Hiyoshi T, Takemura T, Kurashima C, Hirokawa K. Focal lymphocytic inÞltration in the adrenal cortex of the elderly: immunohistological analysis of inÞltrating lymphocytes. Clin Exp Immunol. 1989;77:101Ð5.

123.Alesci S, Koch CA, Bornstein SR, Pacak K. Adrenal androgens regulation and adrenopause. Endocr Regul. 2001;35:95Ð100.

124.Nakamura Y, Gang HX, Suzuki T, Sasano H, Rainey WE. Adrenal changes associated with adrenarche. Rev Endocr Metab Disord. 2008.

125.Suzuki T, Sasano H, Takeyama J, et al.

Developmental changes in steroidogenic enzymes in human postnatal adrenal cortex: immunohistochemical studies. Clin Endocrinol. 2000;53:739Ð47.

126.Gell JS, Carr BR, Sasano H, et al. Adrenarche results from development of a 3beta-hydroxysteroid dehydrogenase-deÞcient adrenal reticularis. J Clin Endocrinol Metab. 1998;83:3695Ð701.

127.Liu CH, Laughlin GA, Fischer UG, Yen SS. Marked attenuation of ultradian and circadian rhythms of dehydroepiandrosterone in postmenopausal women: evidence for a reduced 17,20-desmolase enzymatic activity. J Clin Endocrinol Metab. 1990;71:900Ð6.

128.Pavlov EP, Harman SM, Chrousos GP, Loriaux DL, Blackman MR. Responses of plasma adrenocorticotropin, cortisol, and dehydroepiandrosterone to ovine corticotropin-releasing hormone in healthy

aging men. J Clin Endocrinol Metab. 1986;62: 767Ð72.

129.Straub RH, Besedovsky HO. Integrated evolutionary, immunological, and neuroendocrine framework for the pathogenesis of chronic disabling inßammatory diseases. FASEB J. 2003;17: 2176Ð83.

130.Valtysd—ttir ST, Wide L, HŠllgren R. Low serum dehydroepiandrosterone sulfate in women with

primary SjšgrenÕs syndrome as an isolated sign of impaired HPA axis function. J Rheumatol.

of pro-inßammatory cytokines in rheumatoid arthritis. Springer Semin Immunopathol. 1998;20: 133Ð47.

134.Aringer M, Smolen JS. Tumour necrosis factor and other proinßammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention. Lupus 2004;13:344Ð7.

135.Straub RH, GlŸck T, Cutolo M, et al. The adrenal steroid status in relation to inßammatory cytokines (interleukin-6 and tumour necrosis factor) in polymyalgia rheumatica. Rheum Ox. 2000;39:624Ð31.

136.Zietz B, Reber T, Oertel M, GlŸck T, Schšlmerich J, Straub RH. Altered function of the hypothalamic stress axes in patients with moderately active systemic lupus erythematosus. II. Dissociation between androstenedione, cortisol, or dehydroepiandrosterone and interleukin 6 or tumor necrosis factor. J Rheumatol. 2000;27:911Ð8.

137.Johnson EO, Kostandi M, Moutsopoulos HM.

HypothalamicÐpituitaryÐadrenal axis function in SjšgrenÕs syndrome: mechanisms of neuroendocrine and immune system homeostasis. Ann NY Acad Sci. 2006;1088: 41Ð51.

138.Labrie F. Intracrinology. Mol Cell Endocrinol. 1991;78:113Ð8.

139.Nestler JE, Barlascini CO, Clore JN, Blackard WG. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab. 1988;66:57Ð61.

140.Spaan M, Porola P, Laine M, Rozman B, Azuma M, Konttinen YT. Healthy human salivary glands contain a DHEA-S processing intracrine machinery, which is deranged in primary SjšgrenÕs syndrome. J Cell Mol Med. 2009;13: 1261Ð70.

141.Simpson ER. Sources of estrogen and their importance. J Steroid Biochem Mol Biol. 2003;86: 225Ð30.

142.Labrie F. Extragonadal synthesis of sex steroids: intracrinology. Ann Endocrinol. 2003 Apr;64: 95Ð107.

143.BŽlanger A, Brochu M, Cliche J. Levels of plasma steroid glucuronides in intact and castrated men with prostatic cancer. J Clin Endocrinol Metab. 1986;62:812Ð5.

144.Macdiarmid F, Wang D, Duncan LJ, Purohit A, Ghilchick MW, Reed MJ. Stimulation of aromatase activity in breast Þbroblasts by tumor necrosis factor alpha. Mol Cell Endocrinol. 1994;106:17Ð21.

145.Purohit A, Ghilchik MW, Duncan L, et al. Aromatase activity and interleukin-6 production

by normal and malignant breast tissues. J Clin Endocrinol Metab. 1995;80:3052Ð8.

146. Weidler C, Struharova S, Schmidt M, Ugele B, Schšlmerich J, Straub RH. Tumor necrosis factor inhibits conversion of dehydroepiandrosterone sulfate (DHEAS) to DHEA in rheumatoid arthritis synovial cells: a prerequisite for local androgen deÞciency. Arthritis Rheum. 2005;52: 1721Ð9.

147.Janele D, Lang T, Capellino S, Cutolo M, Da Silva JA, Straub RH. Effects of testosterone, 17betaestradiol, and downstream estrogens on cytokine secretion from human leukocytes in the presence and absence of cortisol. Ann NY Acad Sci. 2006;1069:168Ð82.

148.Cutolo M, Accardo S, Villaggio B, et al. Androgen metabolism and inhibition of interleukin-1 synthesis in primary cultured human synovial macrophages. Mediators Inßamm. 1995;4:138Ð43.

149.Zoukhri D. Effect of inßammation on lacrimal gland function. Exp Eye Res. 2006;82:885Ð98.

150.Laine M, Porola P, Udby L, et al. Low salivary dehydroepiandrosterone and androgen-regulated cysteine-rich secretory protein 3 in SjšgrenÕs syndrome. Arthritis Rheum. 2007;56:2575Ð84.

151.Sato M, Azuma M, Hayashi Y, Yoshida H, Yanagawa T, Yura Y. 5-Azacytidine induction of stable myoepithelial and acinar cells from a human salivary intercalated duct cell clone. Cancer Res. 1987;47:4453Ð9.

152.Man YG, Ball WD, Marchetti L, Hand AR. Contributions of intercalated duct cells to the normal parenchyma of submandibular glands of adult rats. Anat Rec. 2001;263:202Ð14.

153.Shirasuna K, Sato M, Miyazaki T. A neoplastic epithelial duct cell line established from an irradiated human salivary gland. Cancer. 1981;48: 745Ð52.

154.Royce LS, Kibbey MC, Mertz P, Kleinman HK, Baum BJ. Human neoplastic submandibular intercalated duct cells express an acinar phenotype when cultured on a basement membrane matrix. Differentiation 1993;52:247Ð55.

155.Hoffman MP, Kibbey MC, Letterio JJ, Kleinman HK. Role of laminin-1 and TGF-β3 in acinar differentiation of a human submandibular gland cell line (HSG). J Cell Sci. 1996;109:2013Ð21.

156.Laine M, Virtanen I, Porola P, et al. Acinar epithelial cell laminin-receptors in labial salivary glands in SjšgrenÕs syndrome. Clin Exp Rheumatol. 2008;26:807Ð13.

157.Porola P, Laine M, Virtanen I, PšllŠnen R, Przybyla BD, Konttinen YT. Androgens and integrins in salivary glands in SjogrenÕs syndrome. J Rheumatol. 2010;37(6):1181Ð7.

158.Laine M, Virtanen I, Salo T, Konttinen YT. Segment-speciÞc but pathologic laminin isoform proÞles in human labial salivary glands of patients with SjšgrenÕs syndrome. Arthritis Rheum. 2004;50:3968Ð73.

159.Poduval P, Sillat T, Virtanen I, Porola P, Konttinen YT. Abnormal basement membrane type IV collagen alpha chain composition in labial salivary glands in SjšgrenÕs syndrome. Arthritis Rheum. 2009;60:938Ð45.

160.KatsiÞs GE, Moutsopoulos NM, Wahl SM. T lymphocytes in SjšgrenÕs syndrome: contributors to and regulators of pathophysiology. Clin Rev Allergy Immunol. 2007;32:252Ð64.

161.Sakai A, Sugawara Y, Kuroishi T, Sasano T, Sugawara S. IdentiÞcation of IL-18 and Th17 cells in salivary glands of patients with SjšgrenÕs syndrome, and ampliÞcation of IL-17-mediated secretion of inßammatory cytokines from salivary gland cells by IL-18. J Immunol. 2008;181: 2898Ð906.

162.Nguyen CQ, Hu MH, Li Y, Stewart C, Peck AB.

Salivary gland tissue expression of interleukin23 and interleukin-17 in SjšgrenÕs syndrome: Þndings in humans and mice. Arthritis Rheum. 2008;58:734Ð43.

163.Manavalan SJ, Valiando JR, Reeves WH, et al. Genomic absence of the gene encoding T cell receptor Vbeta7.2 is linked to the presence of autoantibodies in SjšgrenÕs syndrome. Arthritis Rheum. 2004;50:187Ð98.

164.Yamamoto K. Pathogenesis of SjšgrenÕs syndrome. Autoimmun Rev. 2003;2:13Ð8.

165.Ramos-Casals M, Font J. Primary SjšgrenÕs syndrome: current and emergent aetiopathogenic concepts. Rheumatology (Oxford) 2005;44: 1354Ð67.

166.Youinou P, Devauchelle V, Hutin P, Le Berre R, Saraux A, Pers JO. A conspicuous role for B cells in SjšgrenÕs syndrome. Clin Rev Allergy Immunol. 2007;32:231Ð7.

167.Szodoray P, Jonsson R. The BAFF/APRIL system in systemic autoimmune diseases with a special emphasis on SjšgrenÕs syndrome. Scand J Immunol. 2005;62:421Ð8.

168.Sfriso P, Oliviero F, Calabrese F, et al. Epithelial CXCR3-B regulates chemokines bioavailability in

normal, but not in SjšgrenÕs syndrome, salivary glands. J Immunol. 2006;176:2581Ð89.

169.Dšrner T, Lipsky PE. Abnormalities of B cell phenotype, immunoglobulin gene expression and the emergence of autoimmunity in SjšgrenÕs syndrome. Arthritis Res. 2002;4:360Ð71.

170.Koski H, Konttinen YT, Xu-Hong G, Hietanen J, Malmstršm M. Transforming growth factor β 2 in labial salivary glands in SjšgrenÕs syndrome. Ann Rheum Dis. 1995;54:744Ð7.

171.BŒve U, Nordmark G, Lšvgren T, et al. Activation of the type I interferon system in primary SjšgrenÕs syndrome: a possible etiopathogenic mechanism. Arthritis Rheum. 2005;52:1185Ð95.

172.Shiozawa S, Tanaka Y, Shiozawa K. Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with SjšgrenÕs syndrome. J Interferon Cytokine Res. 1998;18: 255Ð62.

173.Mariette X, Ravaud P, Steinfeld S, et al. InefÞcacy of inßiximab in primary SjšgrenÕs syndrome: results of the randomized, controlled trial of remicade in primary SjšgrenÕs syndrome (TRIPSS). Arthritis Rheum. 2004;50:1270Ð6.

174.Main C, Blennerhassett P, Collins SM. Human recombinant interleukin 1 beta suppresses acetylcholine release from rat myenteric plexus. Gastroenterology 1993;104:1648Ð54.

175.Cao W, Cheng L, Behar J, Fiocchi C, Biancani P, Harnett KM. Proinßammatory cytokines alter/reduce esophageal circular muscle contraction in experimental cat esophagitis. Am J Physiol Gastrointest Liver Physiol. 2004;287:G1131Ð9.

176.Azuma M, Motegi K, Aota K, Hayashi Y, Sato M. Role of cytokines in the destruction of acinar structure in SjšgrenÕs syndrome salivary glands. Lab Invest. 1997;77:269Ð80.

177.Azuma M, Ashida Y, Tamatani T, et al. Cepharanthin, a biscoclaurine alkaloid, prevents destruction of acinar tissues in murine SjšgrenÕs syndrome. J Rheumatol. 2006;33:912Ð20.

178.Hanemaaijer R, Visser H, Konttinen YT, Koolwijk P, Verheijen J. A novel and simple immunocapture assay for determination of gelatinase-B (MMP-9) activities in biological ßuids: saliva from patients with SjšgrenÕs syndrome contain increased latent and active gelatinase-B levels. Matrix Biol. 1998;17:657Ð65.

179.Konttinen YT, Halinen S, Hanemaaijer R, et al. Matrix metalloproteinase (MMP)-9 type IV collagenase/gelatinase implicated in the pathogene-

sis of SjšgrenÕs syndrome. Matrix Biol. 1998;17: 335Ð47.

180. PŽrez P, Goicovich E, Alliende C, Aguilera S, Leyton C, Molina C, Pinto R, Romo R, Martinez B, Gonz‡lez. Differential expression of

matrix metalloproteinases in labial salivary glands of patients with primary SjšgrenÕs syndrome. Arthritis Rheum. 2000;43:2807Ð17.

181.Goicovich E, Molina C, PŽrez P, et al. Enhanced degradation of proteins of the basal lamina and

stroma by matrix metalloproteinases from the salivary glands of SjšgrenÕs syndrome patients: correlation with reduced structural integrity of acini and ducts. Arthritis Rheum. 2003;48: 2573Ð84.

182.Bombardieri M, Barone F, Pittoni V, et al. Increased circulating levels and salivary gland expression of interleukin-18 in patients with SjšgrenÕs syndrome: relationship with autoantibody production and lymphoid organization of the periductal inßammatory

inÞltrate. Arthritis Res. 2004;6:447Ð56.

mary SjšgrenÕs syndrome, rheumatoid arthritis and healthy controls. Clin Exp Immunol. 2004;137:

and factors associated with high risk of lymphoma development. Arthritis Rheum. 2007;56: 3977Ð88.

185.Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X. B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary SjšgrenÕs syndrome. Scand J Immunol. 2008;67:185Ð92.

186.Ding C. Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inßammatory autoimmune diseases. Expert Opin Biol Ther. 2008;8:1805Ð14.

187.Gatto B. Atacicept, a homodimeric fusion protein for the potential treatment of diseases triggered by plasma cells. Curr Opin Investig Drugs. 2008;9:1216Ð27.

188.Le Pottier L, Bendaoud B, Dueymes M, et al. BAFF, a new target for intravenous immunoglobulin in autoimmunity and cancer. J Clin Immunol. 2007;27:257Ð65.

189.Robinson CP, Yamamoto H, Peck AB, HumphreysBeher MG. Genetically programmed development of salivary gland abnormalities in the NOD (nonobese diabetic)-scid mouse in the absence of detectable lymphocytic inÞltration: a potential trigger for sialoadenitis of NOD mice. Clin Immunol Immunopathol. 1996;79:50Ð9.